Eberhard-karls-universitat Tubingen

Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts

Probiocon Gmbh

Deutsches Krebsforschungszentrum

Julius-maximilians-universitat Wurzburg

Helmut Salih

Latifa Zekri-Metref

Fabian Vogt

Gundram Jung

Andreas Herrmann

Ludger Grosse-Hovest

Hans-Georg Kopp

Stefanie Maurer

Jung Gundram

Berit Lochmann

Gernot Stuhler

Cornelia Lindner

Isabelle Ehnes

Martin Pflügler

The present invention provides a novel PSMA binding antibody termed 10B3 and pharmaceutical and diagnostic uses of the antibody 10B3. The PSMA antibody 10B3 does not cross-compete with the state of the art PMSA binding antibody J591 and has a reduced induction of antigen shift compared to J591 and a unique reactivity with squamous cell carcinoma (SCC) cells of different origin.

PSMA binding antibody and uses thereof

The present invention provides novel human fins related tyrosine kinase 3 (FLT) antigen binding proteins, such as antibodies, having improved FLTbinding affinity, and/or anti-tumor activity. The FLTantibodies of the invention were generated by mutation of a parent FLTantibody and tested in in vitro in binding assays as well as in vivo in a mouse tumor model and in human patient tumor samples. The antibodies of the invention are provided as monospecific constructs or in a bispecific FLT×CDantibody format and show excellent target affinity and/or tumor cell killing. The present invention also relates methods for producing the antigen binding proteins of the invention as well as nucleic acids encoding them, vectors for and host cells for their expression. The invention further relates to methods of treating or diagnosing a disease such as leukemia using an FLTantigen binding protein (ABP) of the invention.

Anti-FLTantigen binding proteins

The invention provides for a RANKL-specific antagonistic agent recognizing human platelet-expressed receptor activator of nuclear factor kappa-B ligand (pRANKL), for use in treating a cancer patient to prevent or reduce premetastatic lesions in blood.

RANKL-specific agent for treating metastatic disease

The present invention relates to fusion proteins comprising a binding protein and an IL-15 polypeptide as well as uses thereof, pharmaceutical compositions comprising such fusion proteins and a method for producing such fusion proteins.

Fusion proteins comprising a binding protein and an interleukin-15 polypeptide having a reduced affinity for IL15Ra and therapeutic uses thereof

Growing community of inventors

Stuttgart, Germany

Helmut Salih